hexamethonium has been researched along with Adenocarcinoma in 2 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schuller, HM | 2 |
| Cole, B | 1 |
2 other studies available for hexamethonium and Adenocarcinoma
| Article | Year |
|---|---|
Regulation of cell proliferation by beta-adrenergic receptors in a human lung adenocarcinoma cell line.
Topics: Adenocarcinoma; Cell Division; Cell Line; Hexamethonium; Hexamethonium Compounds; Humans; Lung Neopl | 1989 |
Cell type specific, receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines.
Topics: Adenocarcinoma; Carcinogens; Cell Division; Diethylnitrosamine; Hexamethonium; Hexamethonium Compoun | 1989 |